Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network

IF 14.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-08-26 DOI:10.1002/hem3.70177

Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, Cihan Ay, Ramon Lecumberri, Alessandra Laroca, Gordon Cook, Monika Engelhardt, Sonja Zweegman, Michel Delforge, Anthony Maraveyas, Eleftheria Lefkou, Marina Marchetti, Niels W. C. J. Van de Donk, Francesca Gay, Heinz Ludwig, Hermann Einsele, Jesus F. San Miguel, Meletios A. Dimopoulos, Mario Boccadoro, Pieter Sonneveld, Anna Falanga, Evangelos Terpos

{"title":"Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network","authors":"Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, Cihan Ay, Ramon Lecumberri, Alessandra Laroca, Gordon Cook, Monika Engelhardt, Sonja Zweegman, Michel Delforge, Anthony Maraveyas, Eleftheria Lefkou, Marina Marchetti, Niels W. C. J. Van de Donk, Francesca Gay, Heinz Ludwig, Hermann Einsele, Jesus F. San Miguel, Meletios A. Dimopoulos, Mario Boccadoro, Pieter Sonneveld, Anna Falanga, Evangelos Terpos","doi":"10.1002/hem3.70177","DOIUrl":null,"url":null,"abstract":"<p>Venous thromboembolism (VTE) is a frequent complication in patients with multiple myeloma (MM) that leads to increased morbidity, mortality, treatment interruptions, and reduced quality of life. Αn Expert Panel Consensus Guideline on behalf of the European Myeloma Network provides evidence-based recommendations for VTE prevention and treatment in patients with MM. Key recommendations include the following:\n\n </p><p>By implementing these guidelines, healthcare providers can improve the prevention and treatment of VTE in patients with MM, leading to better clinical outcomes and quality of life.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 8","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70177","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.70177","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Venous thromboembolism (VTE) is a frequent complication in patients with multiple myeloma (MM) that leads to increased morbidity, mortality, treatment interruptions, and reduced quality of life. Αn Expert Panel Consensus Guideline on behalf of the European Myeloma Network provides evidence-based recommendations for VTE prevention and treatment in patients with MM. Key recommendations include the following:

By implementing these guidelines, healthcare providers can improve the prevention and treatment of VTE in patients with MM, leading to better clinical outcomes and quality of life.

查看原文本刊更多论文

多发性骨髓瘤患者静脉血栓栓塞的预防和治疗：代表欧洲骨髓瘤网络的临床实践指南

静脉血栓栓塞（VTE）是多发性骨髓瘤（MM）患者的常见并发症，可导致发病率、死亡率增加、治疗中断和生活质量下降。Αn代表欧洲骨髓瘤网络的专家小组共识指南为MM患者静脉血栓栓塞的预防和治疗提供了基于证据的建议。主要建议包括：通过实施这些指南，医疗保健提供者可以改善MM患者静脉血栓栓塞的预防和治疗，从而获得更好的临床结果和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.